JP2005530771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530771A5 JP2005530771A5 JP2004503057A JP2004503057A JP2005530771A5 JP 2005530771 A5 JP2005530771 A5 JP 2005530771A5 JP 2004503057 A JP2004503057 A JP 2004503057A JP 2004503057 A JP2004503057 A JP 2004503057A JP 2005530771 A5 JP2005530771 A5 JP 2005530771A5
- Authority
- JP
- Japan
- Prior art keywords
- different
- same
- complex
- complex according
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000006495 integrins Human genes 0.000 description 7
- 108010044426 integrins Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 229940088623 biologically active substance Drugs 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- -1 C 6 hydrocarbon Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DXYNJHYPRKUMLM-WRBBJXAJSA-N 2,3-bis[(z)-octadec-9-enoxy]propyl-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]-dimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCOCCOCCO)OCCCCCCCC\C=C/CCCCCCCC DXYNJHYPRKUMLM-WRBBJXAJSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HBZFNHMNLAOGPI-JDVCJPALSA-N CCCCCCCC/C=C\CCCCCCCC(OC(C)C(C)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O.CN(C)C Chemical compound CCCCCCCC/C=C\CCCCCCCC(OC(C)C(C)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O.CN(C)C HBZFNHMNLAOGPI-JDVCJPALSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0210538.5A GB0210538D0 (en) | 2002-05-08 | 2002-05-08 | Lipids and gene delivery |
| PCT/GB2003/001985 WO2003094974A1 (en) | 2002-05-08 | 2003-05-08 | Complexes for the delivery of biologically-active material to cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530771A JP2005530771A (ja) | 2005-10-13 |
| JP2005530771A5 true JP2005530771A5 (https=) | 2006-06-22 |
Family
ID=9936285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503057A Pending JP2005530771A (ja) | 2002-05-08 | 2003-05-08 | 生物学的活性物質の細胞への運搬に適した複合体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1506019A1 (https=) |
| JP (1) | JP2005530771A (https=) |
| AU (1) | AU2003240997A1 (https=) |
| GB (1) | GB0210538D0 (https=) |
| WO (1) | WO2003094974A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313132D0 (en) | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
| WO2005117985A2 (en) * | 2004-06-02 | 2005-12-15 | Ucl Biomedica Plc | Lipopolyplex construct with an integrin binding peptide for delivery of nucleic acids, peptides or drugs |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| JP7735624B2 (ja) * | 2020-08-31 | 2025-09-09 | 武田薬品工業株式会社 | 推論装置、推論方法、推論プログラム、モデル生成方法、推論サービス提供システム、推論サービス提供方法及び推論サービス提供プログラム |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| ATE195181T1 (de) * | 1995-09-11 | 2000-08-15 | Jolla Cancer Res Found | Moleküle, die sich in ausgewählten organen oder geweben invivo einfinden und verfahren zu ihrer identifizierung |
| US5869715A (en) * | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
| AU7078396A (en) * | 1995-09-27 | 1997-04-30 | Regents Of The University Of California, The | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes |
| GB9711115D0 (en) * | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
| DE60039198D1 (de) * | 1999-03-26 | 2008-07-24 | Vical Inc | Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen |
| DE60016205T2 (de) * | 1999-05-28 | 2005-12-01 | Vical, Inc., San Diego | Cytofectin-dimere und verfahren zu ihrer anwendung |
-
2002
- 2002-05-08 GB GBGB0210538.5A patent/GB0210538D0/en not_active Ceased
-
2003
- 2003-05-08 WO PCT/GB2003/001985 patent/WO2003094974A1/en not_active Ceased
- 2003-05-08 JP JP2004503057A patent/JP2005530771A/ja active Pending
- 2003-05-08 EP EP03730315A patent/EP1506019A1/en not_active Withdrawn
- 2003-05-08 AU AU2003240997A patent/AU2003240997A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230132645A1 (en) | Lipid membrane structure for delivery into sirna cell | |
| Habrant et al. | Design of ionizable lipids to overcome the limiting step of endosomal escape: application in the intracellular delivery of mRNA, DNA, and siRNA | |
| US4897355A (en) | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor | |
| WO2022140239A1 (en) | Nanomaterials comprising carbonates | |
| JP4714289B2 (ja) | リン脂質類似化合物 | |
| CN114073677B (zh) | 一种脂质纳米颗粒 | |
| EP4281064A1 (en) | Nanomaterials comprising an ionizable lipid | |
| JP2017500865A (ja) | レプチンｍＲＮＡの組成物および製剤 | |
| JP7821776B2 (ja) | 効率的な核酸送達のための担体 | |
| US20250381139A1 (en) | Multi-tail type ionizable lipid, preparation method therefor and use thereof | |
| JP6605477B2 (ja) | 核酸送達のためのカチオン性脂質 | |
| WO2024014512A1 (ja) | 核酸内封脂質ナノ粒子の凍結乾燥組成物 | |
| TWI876778B (zh) | 用於傳遞核酸的基於環烷的脂質化合物以及包括其之脂質奈米粒子 | |
| CN118271388A (zh) | 一种类固醇-阳离子脂质化合物及其应用 | |
| JP2010504929A (ja) | 生体系への送達を高める手段及び方法 | |
| JP2005530771A5 (https=) | ||
| CN113403313B (zh) | 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用 | |
| EA018111B1 (ru) | Конъюгаты белок-полимер и способ лечения инфекции вируса гепатита c или гепатита b | |
| JP6774965B2 (ja) | カチオン性脂質としての化合物 | |
| WO2024131717A1 (zh) | 一种阳离子脂质材料的制备及应用 | |
| WO2025224684A1 (en) | Compositions and methods for producing engineered immune cells | |
| CN121378329A (zh) | 一种磷硫化可电离脂质及其制备方法和应用 | |
| WO2025161943A1 (zh) | 用于递送的脂质化合物和脂质纳米颗粒 | |
| WO2025063214A1 (ja) | 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法 | |
| EA022354B1 (ru) | Терапевтическое применение конъюгатов интерферон-пэг |